Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
Read More
3 minute read

Merck’s KEYTRUDA Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone In Patients With HER2-Negative Gastric Or Gastroesophageal Junction Adenocarcinoma Regardless Of PD-L1 Expression

By Happy Mohamed
Today, 12:08 PM
In KEYNOTE-859, KEYTRUDA combined with chemotherapy also showed statistically significant improvements in progression-free survival and objective response rate, the trial's key secondary endpoints, compared with

MRK

Read More
1 minute read

AstraZeneca And Merck Announced Results From The Final Analysis Of Overall Survival From Phase 3 Propel Trial Of Lynparza Plus Abiraterone And Prednisone Or Prednisolone (Abi/Pred), Compared To Placebo Plus Abi/Pred. Did Not Reach Statistical Significa…

By Benzinga Newsdesk
Today, 12:08 PM
Median OS was 42.1 months for the LYNPARZA plus abi/pred arm versus 34.7 months for the placebo plus abi/pred arm, representing a 7.4-month absolute difference in median OS versus a standard of care

AZN

Read More
5 minute read

EXCLUSIVE: How To Lower The Cost Of Cannabis Quality And Save 30% Of Your Top-Line Revenue

By Nicolas Jose Rodriguez
Today, 12:08 PM
Cannabis companies of all sizes are struggling to increase their profit margins and to make that happen, they're implementing different strategies. Lowering prices and premiumizing products are among the alternatives to create value. In addition, cannabis companies might look at risk mitigation as an alternative to achieve higher quality and prevent losses.

BAYRY